A Phase 3 interventional study of Thalidomide and Dexamethasone in Multiple Myeloma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing liposomal doxorubicin in Multiple Myeloma — none open to participants now, none under way, none of them phase 3. liposomal doxorubicin · Multiple Myeloma.
Among the 25 studies testing liposomal doxorubicin in Multiple Myeloma, this one has the largest enrollment, is one of 4 that started in 2005, is the only one in phase 3, and was the 2nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 25 studies testing liposomal doxorubicin in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 1
First in 2002; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 35 across the 25 interventional studies. Of the 21 that completed or were terminated, 13 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 30th largest by enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2005, is one of 35 in phase 3, and was the 3rd registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing liposomal doxorubicin in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
This is a multi-center, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance) study to compare the safety and effectiveness of Thalidomide + Dexamethasone versus DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone in patients with newly diagnosed multiple myeloma. Treatments are administered in 28-day cycles. Patients will receive 4 to 12 treatment cycles, depending on the response of their multiple myeloma to the treatment (measured according to the European Group for Blood and Marrow Transplant Response Criteria). Patients will have additional tests that include Multiple Gated Acquisition (MUGA) scans or echocardiograms to assess the patients for potential cardiotoxicity that could be related to treatment with DOXIL (doxorubicin HCl liposome injection). Maximum duration of study participation for each participant will be 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Thalidomide · Drug: Dexamethasone
Drug: Thalidomide · Drug: Dexamethasone · Drug: DOXIL
Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
Complete Response Rate: Number of Participants Who Achieved a Complete Response
Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.
Time frame: From Cycle 2 until 28 days following completion of treatment
Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)
Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
Time frame: From Cycle 2 until 28 days following completion of treatment
Time to 1st Response
Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
Time frame: From Cycle 2 until 28 days following completion of treatment
Time to Progression
Time to progression is the interval between the date of randomization until disease progression or death due to progression.
Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit
Overall Survival: Number of Participants Died Due to Any Cause
Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit
Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)
Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit
Engraftment: Number of Participants Who Underwent Engraftment
Engraftment is the process of transplanted stem cells reproducing new cells.
Time frame: From randomization until death or as assessed up to 2 years post last participant last treatment visit
| Milestone | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Started | 113 | 112 |
| Received study medication | 110 | 106 |
| Completed | 7 | 12 |
| Not completed | 106 | 100 |
| Withdrew: Adverse event | 31 | 44 |
| Withdrew: Withdrawal by subject | 10 | 8 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Death | 2 | 4 |
| Withdrew: Physician decision | 7 | 1 |
| Withdrew: Disease progression | 8 | 2 |
| Withdrew: Transplant planned | 28 | 27 |
| Withdrew: Other | 19 | 13 |
Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.
| Participants | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Complete Response Rate: Number of Participants Who Achieved a Complete Response | 5 | 8 |
Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
| Participants | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) | 81 | 76 |
Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
| Days | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Time to 1st Response | 44 (37 to 58) | 58 (44 to 60) |
Time to progression is the interval between the date of randomization until disease progression or death due to progression.
| Days | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Time to Progression | 584 (347 to NA) | 408 (350 to 597) |
| Participants | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Overall Survival: Number of Participants Died Due to Any Cause | 21 | 22 |
| Participants | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow) | 30 | 28 |
Engraftment is the process of transplanted stem cells reproducing new cells.
| Participants | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Engraftment: Number of Participants Who Underwent Engraftment | 25 | 25 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Thalidomide + Dexamethasone | — | 48/110 (43.6%) | 110/110 (100%) |
| DOXIL + Thalidomide + Dexamethasone | — | 53/106 (50%) | 104/106 (98.1%) |
| Event | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| PneumoniaInfections and infestations | 5/110 | 7/106 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/110 | 1/106 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 6/110 | 4/106 |
| SyncopeNervous system disorders | 4/110 | 5/106 |
| Renal FailureRenal and urinary disorders | 5/110 | 3/106 |
| Deep Vein ThrombosisVascular disorders | 5/110 | 4/106 |
| PyrexiaGeneral disorders | 1/110 | 4/106 |
| DehydrationMetabolism and nutrition disorders | 4/110 | 3/106 |
| AnaemiaBlood and lymphatic system disorders | 2/110 | 3/106 |
| Atrial FibrillationCardiac disorders | 3/110 | 3/106 |
| Event | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone |
|---|---|---|
| Oedema PeripheralGeneral disorders | 53/110 | 60/106 |
| FatigueGeneral disorders | 58/110 | 58/106 |
| ConstipationGastrointestinal disorders | 45/110 | 48/106 |
| NauseaGastrointestinal disorders | 26/110 | 39/106 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 3/110 | 39/106 |
| AnaemiaBlood and lymphatic system disorders | 21/110 | 31/106 |
| DizzinessNervous system disorders | 27/110 | 23/106 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/110 | 24/106 |
| InsomniaPsychiatric disorders | 24/110 | 16/106 |
| TremorNervous system disorders | 20/110 | 22/106 |
| Age, Continuous(years) | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone | Total |
|---|---|---|---|
| Mean | 60.29 ± 10.31 | 60.62 ± 10.79 | 60.45 ± 10.53 |
| Sex: Female, Male(Participants) | Thalidomide + Dexamethasone | DOXIL + Thalidomide + Dexamethasone | Total |
|---|---|---|---|
| Female | 51 | 44 | 95 |
| Male | 62 | 68 | 130 |
The record gives a start of Jan 2005, a primary completion of Oct 2007 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2008, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →